Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine

NCT03303092 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

357

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

DRUG: TEV-48125
DRUG: TEV-48125 or placebo
DRUG: Placebo

Sponsor

Otsuka Pharmaceutical Co., Ltd.